TREATMENT OF LEIGH SYNDROME AND LEIGH-LIKE SYNDROME WITH TOCOTRIENOL QUINONES
The present invention relates to methods of treating Leigh Syndrome and Leigh-like Syndrome with tocotrienol quinones, including alpha-tocotrienol quinone, in order to alleviate symptoms of the disease.
1 .- 19 . (canceled)
20 . A composition comprising: alpha-tocotrienol quinone, alpha-tocotrienol hydroquinone, or a mixture thereof; and sesame oil.
21 . The composition of claim 20 , wherein the composition is a pharmaceutical preparation, and wherein the alpha-tocotrienol quinone, alpha-tocotrienol hydroquinone, or mixture thereof, is present in a therapeutically effective amount.
22 . The composition of claim 21 , wherein the alpha-tocotrienol quinone comprises at least about 80% by weight of the tocotrienols and tocotrienol quinones present in the preparation.
23 . The composition of claim 21 , wherein the alpha-tocotrienol quinone comprises at least about 90% by weight of the tocotrienols and tocotrienol quinones present in the preparation.
24 . The composition of claim 21 , wherein the alpha-tocotrienol quinone comprises at least about 90% by weight of the material present in the preparation, excluding the weight of pharmaceutical carriers and excipients.
25 . The composition of claim 20 , wherein the alpha-tocotrienol quinone, alpha-tocotrienol hydroquinone, or mixture thereof is present as the naturally occurring configuration.
26 . The composition of claim 21 , wherein the alpha-tocotrienol quinone, alpha-tocotrienol hydroquinone, or mixture thereof is present as the naturally occurring configuration.
27 . The composition of claim 23 , wherein the alpha-tocotrienol quinone, alpha-tocotrienol hydroquinone, or mixture thereof is present as the naturally occurring configuration.
28 . The composition of claim 21 , wherein the preparation is formulated for administration of a unit dosage form of between about 50 mg to 500 mg of alpha-tocotrienol quinone.
29 . The composition of claim 23 , wherein the preparation is formulated for administration of a unit dosage form of between about 50 mg to 500 mg of alpha-tocotrienol quinone.
30 . The composition of claim 27 , wherein the preparation is formulated for administration of a unit dosage form of between about 50 mg to 500 mg of alpha-tocotrienol quinone.
31 . The composition of claim 21 , wherein the preparation is formulated for administration of alpha-tocotrienol quinone, alpha-tocotrienol hydroquinone, or a mixture thereof at about 1.0 mg/kg to about 30 mg/kg body weight.
32 . The composition of claim 23 , wherein the preparation is formulated for administration of alpha-tocotrienol quinone, alpha-tocotrienol hydroquinone, or a mixture thereof at about 1.0 mg/kg to about 30 mg/kg body weight.
33 . The composition of claim 27 , wherein the preparation is formulated for administration of alpha-tocotrienol quinone, alpha-tocotrienol hydroquinone, or a mixture thereof at about 1.0 mg/kg to about 30 mg/kg body weight.
34 . The composition of claim 21 , wherein the composition is formulated for enteral administration.
35 . The composition of claim 21 , wherein the composition is formulated for oral administration.
36 . The composition of claim 21 , wherein the composition is formulated for administration via feeding tube, feeding syringe, or gastrostomy.
37 . The composition of claim 20 , wherein the composition is a nutraceutical or nutritional formulation.
38 . The composition of claim 37 , wherein the composition is a medical food.